---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-019446"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T16:54:42.220571+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma reports positive H5N1 ferret model data for tivoxavir marboxil

## Summary
- Single oral dose of tivoxavir marboxil increased survival and reduced viral burden in lungs and nasal tissues in ferrets.
- Data consistent with December 2024 murine model results; non-human primate study expected Q1 2025.
- Company plans to approach FDA for accelerated approval under the Animal Rule after primate data.
- Virtual investor update on bird flu program scheduled for March 31, 2025.
- CEO Werner Cautreels and former CDC director Robert Redfield comment on urgency of bird flu threat.

## SEC filing metadata
- accession: 0001104659-25-019446
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465925019446/0001104659-25-019446-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465925019446/tm258064d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-019446
- JSON: https://secwatch.observer/filing/0001104659-25-019446.json
- Plain text: https://secwatch.observer/filing/0001104659-25-019446.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.